Stay updated on Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial
Sign up to get notified when there's something new on the Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial page.

Latest updates to the Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial page
- Check5 days agoChange DetectedRevision: v3.4.3 was added to the page, replacing the previous Revision: v3.4.2.SummaryDifference0.0%

- Check12 days agoChange DetectedA new publication citation is added to the Publications section: Gimenez-Arnau AM et al. Dupilumab Improves Health-Related Quality of Life in Omalizumab-Naive Patients with Chronic Spontaneous Urticaria. Dermatol Ther (Heidelb). 2026 Jan;16(1):549-562 (doi:10.1007/s13555-025-01605-w; Epub 2025 Dec 2). The prior 2025 Dec 2 'Online ahead of print' entry is removed.SummaryDifference0.0%

- Check19 days agoChange DetectedAdded a new publication reference: Casale TB, Saini SS, Ben-Shoshan M, Gimenez-Arnau AM, Bernstein JA, Hayama K, Amin N, Robinson LB, Bauer D, Dakin P, Laws E, Radin A, Makhija M. Dupilumab in Patients With Chronic Spontaneous Urticaria: Phase 3 LIBERTY-CSU CUPID Randomized Clinical Trials. JAMA Dermatol. 2026 Feb 18:e256023.SummaryDifference0.0%

- Check33 days agoChange DetectedAddition of Revision: v3.4.2 is shown on the page. The funding/status notices have been removed (including the lapse in government funding message and the earlier Revision: v3.4.1 reference).SummaryDifference0.2%

- Check40 days agoChange DetectedA site-wide notice regarding a lapse in government funding is displayed, stating information may not be up to date and transactions may not be processed. The page also shows a revision from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check48 days agoChange DetectedEditorial/metadata updates include showing the glossary, updating the QC criteria label, capitalization tweaks for FEAR Act data, and a new revision tag (v3.4.0), and these changes do not affect the core study content or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dupilumab in CSU Patients Unresponsive to Omalizumab Clinical Trial page.